{"id":465,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"modified":"2026-10-01T14:53:48","modified_gmt":"2026-10-01T14:53:48","slug":"ss-31-elamipreotide-vs-forzinity-pourquoi-la-distinction-entre-les-medicaments-prets-a-lemploi-est-importante","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","title":{"rendered":"SS-31, Elamipretide et Forzinity\u00a0: pourquoi la distinction entre m\u00e9dicament fini est importante"},"content":{"rendered":"
SS-31 et elamipretide sont des noms utilis\u00e9s autour du m\u00eame peptide cibl\u00e9 sur les mitochondries, mais Forzinity est un m\u00e9dicament fini sp\u00e9cifique approuv\u00e9 par FDA avec une application, une formulation, des contr\u00f4les de fabrication et une \u00e9tiquette approuv\u00e9s. Un nom d\u2019ingr\u00e9dient correspondant ne cr\u00e9e pas d\u2019\u00e9quivalence pharmaceutique.<\/p>
Ce que montre le dossier<\/h2>
L'indication approuv\u00e9e est limit\u00e9e aux patients atteints du syndrome de Barth pesant au moins 30 kg.<\/li>
L\u2019approbation acc\u00e9l\u00e9r\u00e9e ne supprime pas l\u2019exigence de preuves de confirmation.<\/li>
Un lot SS-31 du catalogue doit \u00eatre d\u00e9crit par son propre enregistrement analytique, et non en empruntant le statut du produit approuv\u00e9.<\/li><\/ul><\/div><\/div>Illustration \u00e9ditoriale originale utilis\u00e9e pour identifier le th\u00e8me de recherche. Il ne d\u00e9crit pas un lot catalogue, un m\u00e9dicament approuv\u00e9, un r\u00e9sultat de test ou une utilisation clinique.<\/figcaption><\/figure>
La fronti\u00e8re entre l\u2019identit\u00e9 et la preuve<\/h2>
L'application FDA comprend des informations sp\u00e9cifiques au produit sur la chimie, la fabrication, la s\u00e9curit\u00e9 et l'\u00e9tiquetage. Rien de tout cela n\u2019est transf\u00e9r\u00e9 automatiquement \u00e0 un mat\u00e9riau distinct portant un nom d\u2019\u00e9lamipr\u00e9tide ou de SS-31.<\/p>
Produit fini approuv\u00e9<\/strong>Forzinity (\u00e9lamipr\u00e9tide)<\/span><\/div>
Limite d'indication<\/strong>syndrome de Barth\u00a0; poids corporel d'au moins 30 kg<\/span><\/div>
Dossier de mat\u00e9riel de recherche<\/strong>S\u00e9quence, forme, dosage, impuret\u00e9s et tra\u00e7abilit\u00e9 des lots<\/span><\/div><\/div><\/div>
Ce qui appartient au dossier mat\u00e9riel<\/h2>
La copie de recherche doit indiquer quel est le lot du catalogue et comment il a \u00e9t\u00e9 test\u00e9. Il ne doit pas indiquer \u00ab SS-31 approuv\u00e9 par FDA \u00bb \u00e0 moins qu'il ne s'agisse du produit fini approuv\u00e9 dans son contexte r\u00e9glementaire exact.<\/p>
R\u00e8gle \u00e9ditoriale<\/h2>
Utilisez le nom exact de l\u2019intervention, le mod\u00e8le, la population et le point final de l\u2019enregistrement cit\u00e9. Ne convertissez pas une association, un m\u00e9canisme, un r\u00e9sultat animal, un dossier de m\u00e9dicament fini approuv\u00e9 ou un test analytique en une all\u00e9gation concernant un lot du catalogue sans rapport.<\/p>","protected":false},"excerpt":{"rendered":"
SS-31 et elamipretide sont des noms utilis\u00e9s autour du m\u00eame peptide cibl\u00e9 sur les mitochondries, mais Forzinity est un m\u00e9dicament fini sp\u00e9cifique approuv\u00e9 par FDA avec une application, une formulation, des contr\u00f4les de fabrication et une \u00e9tiquette approuv\u00e9s. Un nom d\u2019ingr\u00e9dient correspondant ne cr\u00e9e pas d\u2019\u00e9quivalence pharmaceutique.<\/p>","protected":false},"author":1,"featured_media":4019,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"FDA label\/approval distinction and research-material quality review","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"\n
SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD<\/title>\n<meta name=\"description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/ss-31-elamipreotide-vs-forzinity-pourquoi-la-distinction-entre-les-medicaments-prets-a-lemploi-est-importante\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\" \/>\n<meta property=\"og:description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/ss-31-elamipreotide-vs-forzinity-pourquoi-la-distinction-entre-les-medicaments-prets-a-lemploi-est-importante\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-01T14:53:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-10-01T14:53:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"wordCount\":246,\"commentCount\":1,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-465.jpg\",\"articleSection\":[\"Evidence & Quality Guides\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-465.jpg\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-10-01T14:53:48+00:00\",\"description\":\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-465.jpg\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-465.jpg\",\"width\":1200,\"height\":800,\"caption\":\"Editorial comic illustration: Understanding Elamipretide. Conceptual cover, not experimental imagery.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SS-31, Elamipretide et Forzinity : pourquoi la distinction entre m\u00e9dicament fini est importante - NHD","description":"SS-31 et elamipretide sont des noms utilis\u00e9s autour du m\u00eame peptide cibl\u00e9 sur les mitochondries, mais Forzinity est un m\u00e9dicament fini sp\u00e9cifique approuv\u00e9 par FDA avec un approbation\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/ss-31-elamipreotide-vs-forzinity-pourquoi-la-distinction-entre-les-medicaments-prets-a-lemploi-est-importante\/","og_locale":"fr_FR","og_type":"article","og_title":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","og_description":"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026","og_url":"https:\/\/nhdbio.com\/fr\/ss-31-elamipreotide-vs-forzinity-pourquoi-la-distinction-entre-les-medicaments-prets-a-lemploi-est-importante\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-10-01T14:53:48+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-10-01T14:53:48+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"wordCount":246,"commentCount":1,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-465.jpg","articleSection":["Evidence & Quality Guides"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","url":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","name":"SS-31, Elamipretide et Forzinity : pourquoi la distinction entre m\u00e9dicament fini est importante - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-465.jpg","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-10-01T14:53:48+00:00","description":"SS-31 et elamipretide sont des noms utilis\u00e9s autour du m\u00eame peptide cibl\u00e9 sur les mitochondries, mais Forzinity est un m\u00e9dicament fini sp\u00e9cifique approuv\u00e9 par FDA avec un approbation\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-465.jpg","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-465.jpg","width":1200,"height":800,"caption":"Editorial comic illustration: Understanding Elamipretide. Conceptual cover, not experimental imagery."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=465"}],"version-history":[{"count":2,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/465\/revisions"}],"predecessor-version":[{"id":2819,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/465\/revisions\/2819"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/4019"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Un](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png\")